Survey: MiSeq First Choice for Planned Sequencer Purchases; Labs' Data Output Continues to Grow | GenomeWeb

Two-thirds of laboratories planning to purchase a sequencer within the next 12 months are considering Illumina's MiSeq, according to a recent survey by investment firm Mizuho Securities USA and GenomeWeb.

In the survey, conducted at the end of the first quarter, researchers ranked the Illumina MiSeq higher than the Ion Torrent PGM in seven out of 10 categories.

The HiSeq scored above the Ion Proton in five out of 10 areas, equal in two, and the Proton came out first in three categories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.